PROGRAMME MILESTONES Sample Clauses

PROGRAMME MILESTONES. The following Xxxxx chart illustrates the key deliverables and the delivery milestones (e.g. DM1) for the GDE FF programme at GHNT, broken down into its component work streams and individual projects. In addition, key deliverables have been matched against funding payment milestones. The anticipated start date of this programme is planned for December 2017. All dates in this proposal are subject to change based on this programme initiation. This is also subject to funding and resource allocation. Any critical dependencies on the GDE will be factored into the programme once the individual detail on the projects has been worked through. Project Ref Description of Deliverables Workstream 1 – Governance and infrastructure design Start Date End Date (month/year) (month/year) A1 Funding Agreement Sign Off Nov-17 Jan-18 A2 Delivery Approach and Framework Feb-18 May-18 A3 Programme mobilisation approach Feb-18 May-18 A4 System Topology Mar-18 Jun-18 Workstream 2 – The Agile Clinician B1 Accelerating Patient Flow Feb-18 Dec-18 B2 Live Hospital Management Feb-18 Dec-18 B3 Real time Patient Monitoring Feb-18 Dec-18 B4 Delivering a 24x7 service Apr-18 Jul-19 B5 Clinical Images available anywhere Feb-18 B6 B7 B8 B9 Clinician access to all Images across XxXX and GHNT Digitising Medical Devices Improved Clinical and Operational Decision Making Enabling the Agile Clinician Oct-18 Oct-18 Sep-18 Sep-18 Xxx-00 Xxx-00 Xxx-00 Mar-20 Workstream 3 – The Digital Clinician / Patient C1 Clinical Records available anywhere Feb-18 Oct-18 C2 Clinical Pathway Workflow Transformation Oct-18 Jan-19 C3 Standardisation of Clinical Records Mar-19 Aug-19 C4 Electronic Medicines Management Apr-18 Aug-19 C5 Closed Loop Medicines Jun-19 Sep-20 C6 Paperless Orders and Results Trust wide Apr-18 Mar-20 C7 C8 C9 C10 C11 Hospital at Night Visible Patient Management - Tasks Visible Patient Management - Referrals Patient Self Care and Management Patient Self Check in Feb-18 Sep-18 Jan-19 May-18 Apr-19 Sep-19 Dec-19 Mar-20 Sep-19 Mar-20 Workstream 4 – Clinical Pathway Transformation D1 Single Clinician Portal Jun-18 Jun-20 D2 Paperless Outpatients Apr-18 Oct-18 D3 Paperless Nursing Apr-18 Jul-19 D4 Paperless Community Services Apr-18 Oct-18 D5 Paperless AHPs Apr-18 Dec-19 D6 Paperless Clinicians Apr-18 Mar-20 D7 D8 D9 Paperless Mental Health Paperless Theatres Real time NHS Numbers Apr-18 Oct-18 Dec-18 Mar-19 Jun-19 Jun-20 D10 Improving Patient Outcomes PAYMENT MILESTONES Xxx-00 Xxx-00 0 0 0 0 Xxx-00 D...
Sample 1
AutoNDA by SimpleDocs
PROGRAMME MILESTONES. 4.1 The following milestone dates are provided for information purposes and will be driven by compliance with the Landlord’s, the Tenant’s and the Contractor’s obligations under the Agreement for Lease and the Management Contract.
Sample 1
PROGRAMME MILESTONES. Freezing of main machine parameters Completed in 1976 Final design and call for tenders of main components: --TF-coils, transformer 1977 --vessel 1978 -- first liner 1978-1979 Commissioning of the system including neutral injection 1980-1981
Sample 1
PROGRAMME MILESTONES. 3.1 There are several Phases of the PROGRAMME: - Phase 1: entrance to AAPA leading up to PPL; - Phase 2: after PPL leading up to CPL and CIR; - Phase 3: employment with Rex and entrance to Rex Ground School leading up to type endorsement; - Phase 4: employment with Rex as a First Officer; - Phase 5: entrance into the PICUS programme after meeting all prerequisites and leading up to graduation from PICUS; - Phase 6: entrance into the Command Upgrade leading to graduation as Captain. The above represents the principal progression path of the Cadet. However Rex reserves the right to modify the progression from Phase 3 onwards according to the needs of the Xxx Group while being mindful of the aspirations of the Cadet,
Sample 1
PROGRAMME MILESTONES. 3.1 There are several Phases of the PROGRAMME: − Phase 1: Entrance to AAPA leading up to PPL; − Phase 2: After PPL leading up to and including CPL and CIR; − Phase 3: Employment with Rex and entrance to Rex Ground School leading up to and including type endorsement; − Phase 4: Employment with Rex as a First Officer; − Phase 5: Entrance into the PICUS programme after meeting all prerequisites and leading up to graduation from PICUS. Cadets who, at the sole discretion of Rex, have poor aptitude either in performance or attitude will not be offered a place in PICUS and will remain at Phase 4 for the rest of the PROGRAMME; − Phase 6: Entrance into the Command Upgrade leading to graduation as Captain. The above represents the principal progression path of the Cadet. However Rex reserves the right to modify the progression from Phase 3 onwards according to the needs of the Rex Group and the performance and attitude of the Cadets while being mindful of the aspirations of the Cadet.
Sample 1

Related to PROGRAMME MILESTONES

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Commercial Milestones In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, Licensee shall pay to AstraZeneca the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Sales Milestones Subject to the terms and conditions set forth in the Agreement, in the event that the Annual Net Sales made by or on behalf of a Selling Entity for all Licensed Products in a given calendar year first exceeds a threshold set forth in the table immediately below, Pyxis shall pay to LCB the following one-time, non-refundable, non-creditable milestone payments. Annual Net Sales Milestone Threshold Payment (US Dollars) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] In the event that in a given calendar year more than one (1) Annual Net Sales milestone threshold is achieved, Pyxis shall pay to LCB each separate Annual Net Sales milestone payment with respect to each Annual Net Sales milestone threshold that is achieved in such calendar year. Pyxis shall notify LCB in writing upon the first achievement, in respect of a Licensed Product, by or on behalf of Pyxis or its Affiliate or Sublicensee, of each of the Milestones set forth in Section 5.2 (Development Milestones), Section 5.3 (Regulatory Milestones) and Section 5.4 (Sales Milestones) no later than [***] of Pyxis’s knowledge of achievement thereof, and in any event, each of the Milestones set forth in Section 5.4 (Sales Milestones) no later than [***] after the end of the applicable calendar year in which such Milestone is achieved. No later than [***] of receipt of an appropriate invoice from LCB, Pyxis shall pay the applicable payment due upon achievement of the corresponding Milestone Event. Each Milestone Event shall be deemed to be achieved once for all Licensed Products and shall be payable only once.

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Regulatory Milestones Celgene shall make the following approval milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Regulatory Milestone Events set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Regulatory Milestone Event). CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Regulatory Milestone Event (For the first Co-Co Product that achieves such event) Milestone Payments (in $ millions) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] For each of Paragraphs (1) - (3) of this Exhibit C-2, the Parties understand and agree that in no event will more than one (1) milestone payment be paid with respect to any specific event triggering a payment under this Jounce Lead Co-Co Agreement.

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Milestone Event Milestone Payment [***] [***]

  • Development Milestone Payments In partial consideration for the rights and licenses granted to Coya hereunder, within ten days after the first achievement of each milestone event in a given Indication set forth in this Section 5.2 (Development Milestone Payments) with respect to a Product (each, a “Development Milestone Event”) by or on behalf of Coya or any of its Affiliates or Sublicensees, Coya shall provide ARScience Bio written notice to ARScience Bio identifying the Development Milestone Event achieved. Upon receipt of any such notice of first achievement of a Development Milestone Event by Coya or its Affiliates or Sublicensees, ARScience Bio will promptly invoice Coya for the applicable Development Milestone Event and Coya will make a milestone payment to ARScience Bio in the amount set forth in this Section 5.2 (Development Milestone Payments) corresponding to such Development Milestone Event (each, a “Development Milestone Payment”) within 45 days of receipt of such invoice. On an Indication-by-Indication basis, each Development Milestone Payment shall be payable only upon the first achievement of the corresponding Development Milestone Event by a Product, in any given Indication for which the Development Milestone Events have not been previously achieved (each such Indication, a “New Indication”). No amounts shall be due for subsequent or repeated achievements of such Development Milestone Event with respect to the same or different Mono Product or Combination Product, as applicable, in such Indication. Accordingly and for clarity, the Development Milestone Payment shall be paid only once, when first achieved by Coya, an Affiliate or a Sublicensee, but no payment shall be due if the same milestone is subsequently achieved by one of Coya, an Affiliate or a Sublicensee. For clarity, the amounts owed in Column (a) below shall be due for the first Combination Product to achieve the Development Milestone Events in a New Indication and the amounts owned in Column (c) below shall be due for the first Mono Product to achieve the Development Milestone Events in a New Indication. Any Combination Product or Mono Product to achieve the Development Milestone Events in a New Indication after the first achievement of the Development Milestone Events as described in the foregoing sentence will cause the amounts in Column (b) with respect to a Combination Product and Column (d) with respect to a Mono Product to be due and payable by Coya upon each such occurrence. If the first Product to achieve a Development Milestone Event in any Indication is a Combination Product, the amounts in Column (a) below shall be due and payable by Coya. If the next Product to achieve a Development Milestone Event in a New Indication is a Mono Product, the amounts in Column (c) below would be due and payable by Coya; provided, that if such next Product to achieve a Development Milestone Event in a New Indication is a Combination Product, the amounts in Column (b) would be due and payable by Coya. By way of example, if a Combination Product achieves IND Acceptance in ALS, and is the first Product to achieve a Development Milestone Event under this Agreement, [***] will be due and payable by Coya. If subsequently a Mono Product achieves IND Acceptance in ALS, no Development Milestone Payments will be due and payable by Coya under this Agreement. However, if subsequently any Combination Product achieves IND Acceptance in Alzheimer’s disease, [***] would be due and payable by Coya.

  • Commercial Milestone Payments For each Licensed Product, Licensee shall pay Arvinas the following one-time milestone event payments when the aggregate Net Sales of such Licensed Product in one or more particular country(ies) for a given calendar year (“Annual Net Sales”), where such Licensed Product is a Valid Claim Licensed Product at the time of sale in each of such country(ies), first achieves the corresponding threshold as set forth in this Section 6.3.2 below, subject to the terms of this Section 6.3 and the payment provisions in Article 7 below: Commercial Milestone Event Milestone Event Payment (US$)

Time is Money Join Law Insider Premium to draft better contracts faster.